SCHEMBL19436636

SCHEMBL19436636

CCOC(=O)c1cnn2c(C)cc(NC)nc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.62
HSD17B10 Q99714 8/20 0.62
HPGD P15428 7/20 0.62
ALDH1A1 P00352 7/20 0.62
NPC1 O15118 4/20 0.62
RAB9A P51151 3/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
CASP1 P29466 3/20 0.48
CASP7 P55210 2/20 0.48
TSHR P16473 2/20 0.48
MAPT P10636 4/20 0.47
CSNK1D P48730 1/20 0.46
GAA P10253 2/20 0.45
KLK7 P49862 1/20 0.45
GLA P06280 1/20 0.45
CCNA2 P20248 1/20 0.44
CDK2 P24941 1/20 0.44
TP53 P04637 1/20 0.44
ADORA3 P0DMS8 1/20 0.43
ADORA2A P29274 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19436718 0.85 KDM4E (0.57) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL1006040 0.84 KDM4E (0.68) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL19436696 0.84 KDM4E (0.68) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL14124198 0.83 KDM4E (0.63) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL17732302 0.83 KDM4E (0.66) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL17732301 0.82 KDM4E (0.65) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL19436619 0.80 KDM4E (0.62) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL19436790 0.80 KDM4E (0.62) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL21948230 0.80 KDM4E (0.53) KDM4EHSD17B10HPGDALDH1A1NPC1
SCHEMBL19436669 0.80 KDM4E (0.62) KDM4EHSD17B10HPGDALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators Bial—R&D Investments, S.A. (PT) 2024-10-15 US disclosed
US-20230098494-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. 2023-03-30 US disclosed
CN-109311887-B Pyrazolo [1,5-a ] pyrimidinecarboxamide compounds and their use in the treatment of medical conditions BIAL研发投资股份有限公司 2022-09-13 CN disclosed
US-11192892-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2021-12-07 US disclosed
US-10934298-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders BIAL—BioTech Investments, Inc. (PT) 2021-03-02 US disclosed
US-20190330213-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2019-10-31 US disclosed
EP-3440080-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Lysosomal Therapeutics Inc. (US) 2019-02-13 EP disclosed
US-9840510-B1 Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders LYSOSOMAL THERAPEUTICS INC. (US) 2017-12-12 US disclosed
US-20170349598-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2017-12-07 US disclosed
WO-2017176960-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. (US) 2017-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators GBA1, GALC, GBA3 KDM4E 1067/4885HSD17B10 3819/4885HPGD 2491/4885
US-11192892-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders GBA1, PARK7, GAA KDM4E 889/4885HSD17B10 4094/4885HPGD 1253/4885
US-20170349598-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 KDM4E 690/4885HSD17B10 4115/4885HPGD 1842/4885
US-20230098494-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 KDM4E 690/4885HSD17B10 4115/4885HPGD 1842/4885
US-10934298-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders GBA1, GAA, PARK7 KDM4E 1447/4885HSD17B10 4037/4885HPGD 1492/4885
US-20190330213-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 KDM4E 690/4885HSD17B10 4115/4885HPGD 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.